Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype?
- PMID: 27794126
- DOI: 10.1093/jnci/djw218
Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype?
Comment on
-
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.J Natl Cancer Inst. 2016 Oct 28;109(2):djw207. doi: 10.1093/jnci/djw207. Print 2017 Feb. J Natl Cancer Inst. 2016. PMID: 27794124 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
